Trial
NCT01115803
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Metastases, Neoplasm
Intervention
LY2584702
Why stopped
Primary objective has been met; safety and pharmacokinetics have been characterized.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-02-05